FBB PET/CT Scan: Advanced Amyloid Imaging for Alzheimer's Disease and Dementia Evaluation
Memory loss and cognitive decline can significantly impact a person's quality of life, affecting not only the individual but also their family and loved ones. While occasional forgetfulness is a normal part of aging, persistent memory problems may be an early sign of neurological conditions such as Alzheimer's disease or other forms of dementia.
Accurately identifying the underlying cause of cognitive impairment is essential for appropriate treatment, care planning, and long-term management. Although neurological examinations, cognitive assessments, MRI, and CT scans provide valuable information, they may not always reveal the biological changes occurring within the brain during the early stages of disease.
One of the most significant advancements in neurological imaging is the Florbetaben (FBB) PET/CT Scan, an advanced molecular imaging examination that enables physicians to visualize beta-amyloid plaques in the brain—one of the hallmark pathological features of Alzheimer's disease.
By detecting amyloid deposition in living patients, FBB PET/CT provides valuable information that supports physicians in diagnosing Alzheimer's disease, differentiating it from other causes of dementia, and guiding personalized patient care.
Enhancing the Diagnosis of Memory Disorders Through Advanced Molecular Imaging
What is an FBB PET/CT Scan?
An FBB PET/CT Scan is an advanced diagnostic imaging procedure used to evaluate the presence of beta-amyloid plaques in the brain.
The examination utilizes Florbetaben (FBB), a radiopharmaceutical specifically developed to bind to amyloid plaques. After the tracer is injected into the bloodstream, it travels to the brain and attaches to areas where amyloid plaques are present.
The PET (Positron Emission Tomography) scanner detects the radioactive signal emitted by the tracer, producing detailed images of amyloid distribution throughout the brain. The CT (Computed Tomography) component provides anatomical information that helps accurately localize the PET findings.
Together, PET and CT create comprehensive images that assist physicians in evaluating whether amyloid plaque accumulation is present.
Understanding Alzheimer's Disease and Amyloid Plaques
Alzheimer's disease is the most common cause of dementia, accounting for the majority of dementia cases worldwide.
One of the earliest biological changes associated with Alzheimer's disease is the accumulation of beta-amyloid proteins within the brain. These proteins gradually cluster together to form plaques between nerve cells.
Over time, amyloid plaque accumulation may contribute to:
-
Progressive memory loss
-
Difficulty solving problems
-
Confusion with time or place
-
Changes in language and communication
-
Impaired judgment
-
Personality and behavioral changes
-
Decline in daily functioning
These biological changes often begin years before noticeable symptoms develop.
FBB PET imaging allows physicians to determine whether significant amyloid plaque deposits are present, providing valuable information that cannot be obtained through routine structural imaging alone.
How Does an FBB PET/CT Scan Work?
Why is an FBB PET/CT Scan Performed?
The examination begins with the administration of a small amount of Florbetaben (FBB) through an intravenous injection.
After entering the bloodstream, the tracer crosses into the brain and selectively binds to beta-amyloid plaques.
Patients then rest comfortably during an uptake period that allows the tracer to distribute throughout the brain.
The PET scanner detects the radioactive emissions from the tracer, while the CT scanner provides detailed anatomical images.
Specialized software combines both datasets into highly detailed images that allow physicians to evaluate the distribution and intensity of amyloid plaque accumulation.
FBB PET/CT is not intended as a routine screening examination for everyone with memory complaints. Instead, it is recommended in carefully selected clinical situations where the results are expected to provide meaningful diagnostic information.
Physicians may recommend the examination to:
-
Clarify the cause of unexplained cognitive decline
-
Differentiate Alzheimer's disease from other types of dementia
-
Evaluate patients with atypical or unusual symptoms
-
Support diagnosis in younger patients with early-onset cognitive impairment
-
Assist neurologists when clinical findings remain inconclusive after standard evaluations
-
Help determine whether amyloid-targeting therapies may be appropriate, depending on current clinical guidelines and physician assessment
The examination is always interpreted alongside the patient's medical history, neurological evaluation, cognitive testing, laboratory results, and other imaging studies.
Benefits of FBB PET/CT Imaging
Earlier Detection of Brain Changes
Amyloid plaque accumulation may occur many years before significant structural brain changes become visible on MRI or CT scans.
FBB PET imaging provides physicians with insight into these early biological changes.
Better Differentiation Between Dementias
Not all dementia is caused by Alzheimer's disease.
Different forms of dementia may require different treatment approaches and long-term management strategies.
FBB PET imaging assists physicians in distinguishing Alzheimer's disease from other neurodegenerative disorders.
Safety Information
FBB PET/CT is performed under strict radiation safety standards by trained healthcare professionals.
The amount of radiopharmaceutical administered is carefully calculated to provide excellent image quality while keeping radiation exposure as low as reasonably achievable.
Serious allergic reactions are extremely uncommon.
Patients should inform the imaging team of any allergies, medical conditions, or medications before undergoing the examination.